Kent Dicks on Virtual Care's Rise & Challenges
May 29, 2025 — Explore how Kent Dicks and Life365 are revolutionizing virtual care, tackling clinician burnout, and making healthcare more accessible. Learn about the future of digital health.
Curated Health Wellness News
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
Telomir Pharmaceuticals' Telomir-1 Shows Promise in Reversing Macular Degeneration in Preclinical Study
May 29, 2025 — Telomir Pharmaceuticals announces positive preclinical results for Telomir-1 in reversing retinal degeneration in zebrafish model of AMD. Learn how this breakthrough could lead to regenerative treatments for macular degeneration.
Unbuzzd Wellness Inc. Appoints MNP LLP for PCAOB Audits in Preparation for Potential IPO
May 29, 2025 — Unbuzzd Wellness Inc. appoints MNP LLP for PCAOB audits in preparation for a potential IPO, demonstrating commitment to transparency and financial diligence. Follow the company's journey towards capital raising and public listing advisory.
American Heart Association Urges Families to Learn CPR for a Heart-Healthy Summer
May 29, 2025 — American Heart Association encourages CPR training for families to ensure a heart-healthy summer. Learn how to save lives with CPR, supported by Walgreens. Improve survival rates for cardiac arrest and be prepared for emergencies.
Alzamend Neuro Advances Breakthrough Therapies for Neurological and Psychiatric Conditions
May 29, 2025 — Alzamend Neuro is making strides in developing transformative therapies for Alzheimer’s, BD, MDD, and PTSD. Learn about their breakthrough treatments and the potential impact on patients' lives.
SeaStar Medical Reports Fourfold Increase in QUELIMMUNE Sales, Targets Adult Market
May 29, 2025 — SeaStar Medical reports significant growth in QUELIMMUNE sales and sets sights on the adult AKI market. The company's innovative therapy shows promise for improving patient outcomes and could have a substantial impact on the healthcare industry.
University of Houston Receives $3 Million for Cancer Immunotherapy Biomarker Core
May 29, 2025 — University of Houston receives $3 million grant for cancer immunotherapy biomarker core from Cancer Prevention & Research Institute of Texas. This investment showcases the commitment to innovative cancer research.
Alzamend Neuro Doses First Patient in Phase II Trial of AL001 for Neurological Disorders
May 29, 2025 — Alzamend Neuro announces dosing of first patient in Phase II trial of AL001, a lithium-based therapeutic for Alzheimer’s, bipolar disorder, MDD, and PTSD. Learn more about this breakthrough treatment here.
GeoVax Backs Bipartisan Initiative to Onshore Vaccine Manufacturing
May 29, 2025 — GeoVax supports bipartisan effort to bring vaccine manufacturing back to the U.S., emphasizing the significance of national health security and pandemic preparedness. The company's MVA platform is at the forefront of advancing multi-antigen vaccines for high-risk populations.
Glucotrack to Host Virtual Webinar on CBGM Technology Revolutionizing Diabetes Care
May 29, 2025 — Glucotrack Inc. is set to host a virtual webinar discussing its groundbreaking Continuous Blood Glucose Monitor (CBGM) technology, offering insights into the future of diabetes management. Learn how this innovation could reshape traditional glucose monitoring methods and improve the lives of millions affected by diabetes.
Catalio Capital Joins $130M Series B for GlycoEra's Autoimmune Therapies
May 29, 2025 — Catalio Capital invests in GlycoEra's $130M Series B for autoimmune disease treatments, signaling strong belief in biotech innovation.
Catalio Capital Backs GlycoEra's $130M Series B for Autoimmune Therapies
May 29, 2025 — Catalio Capital joins a $130M Series B funding for GlycoEra, a biotech firm developing innovative treatments for autoimmune diseases, marking a significant step in life sciences investment.
TransCode Therapeutics Names Dr. Phillip D. Zamore to Scientific Advisory Board
May 28, 2025 — TransCode Therapeutics appoints Dr. Phillip D. Zamore, a leading figure in RNA research, to its Scientific Advisory Board. The addition enhances the company's focus on RNA-targeted cancer therapy programs, marking a strategic development in the fight against metastatic disease.
Bioadaptives Reveals Impressive Results for Regen(TM) Dog Chews in Clinical Trials
May 28, 2025 — Bioadaptives showcases remarkable clinical results for Regen(TM) Dog Chews, offering a safe and effective solution for improving canine health and vitality. With a 281.3% increase in circulating stem cells and a proprietary rating system, this premium pet wellness product stands out for its natural ingredients and proven benefits.
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Scientific Advisory Board
May 28, 2025 — TransCode Therapeutics appoints Dr. Phillip D. Zamore, a leading figure in RNA research, to its Scientific Advisory Board, enhancing its cancer therapy programs. The addition of Dr. Zamore underscores the company's commitment to developing innovative RNA therapeutics for metastatic disease.
House Passes Reconciliation Bill Impacting Healthcare and Medicaid
May 28, 2025 — The U.S. House of Representatives approval of the reconciliation bill for the 2025 budget with a one-vote difference will have significant impacts on healthcare insurance and Medicaid. Learn more about the potential changes and implications of this legislation.
Renowned RNA Expert Dr. Phillip D. Zamore Joins TransCode Therapeutics' Scientific Advisory Board
May 28, 2025 — Renowned RNA expert Dr. Phillip D. Zamore joins TransCode Therapeutics' Scientific Advisory Board, enhancing the company's cancer therapy programs. This strategic addition highlights the potential of RNA therapeutics for treating metastatic tumors and revolutionizing oncology.
Quantum BioPharma Receives Approval for Phase 2 Clinical Trial of FSD202 for Chronic Pain Associated with MCAS
May 28, 2025 — Quantum BioPharma (NASDAQ: QNTM) receives approval for Phase 2 clinical trial of FSD202, a potential treatment for chronic pain associated with MCAS. The trial aims to measure pain reduction over 56 days, offering hope for patients with this debilitating disorder.
NanoViricides to Present at BIO International Convention 2025, Showcasing Antiviral Drug Pipeline
May 28, 2025 — NanoViricides, Inc. (NNVC) to present at BIO International Convention 2025 in Boston, discussing antiviral drug pipeline including NV-387. Learn more about the company's innovative approach to viral treatment.
HCTI Secures Multi-Year Wins and Expands AI Services in Healthcare Sector
May 28, 2025 — Healthcare Triangle, Inc. (HCTI) announces new strategic contracts and AI advancements in the healthcare sector, positioning the company as a key player in digital transformation solutions for improved patient care.